Clinical Trial Update: Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer [Phase 2, Phase 3]

View source ↗

Summary

The clinical trial evaluating B013 in combination with Nab-Paclitaxel for locally advanced or metastatic triple-negative breast cancer has completed Phase 2 and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• B013
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd | Conditions: Triple Negative Breast Cancer (TNBC) | Phase 2, Phase 3 | Status: COMPLETED